Analysis of Strategy for Proof of Efficacy for Drugs Designated as Particularly High Medical Necessities in Japan-Reference-Cited by-同舟云学术

Analysis of Strategy for Proof of Efficacy for Drugs Designated as Particularly High Medical Necessities in Japan

Published:2022-05-31 Issue:3 Volume:53 Page:39-47
ISSN:0388-1601
Container-title:Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics
language:en
Short-container-title:Jpn. J. Clin. Pharmacol. Ther.

Author:

SHIRAI Toshiaki¹,NAGAI Naomi¹

Affiliation:

1. Research Institute of Pharmaceutical Sciences, Musashino University, Japan

Publisher

Japanese Society of Clinical Pharmacology and Therapeutics

Subject

Pharmacology (medical),Pharmacology

Link

https://www.jstage.jst.go.jp/article/jscpt/53/3/53_39/_pdf

Reference39 articles.

1. 1) Pharmaceuticals and Medical Devices Agency. Considerations for reviewers involving new drug approval reviews.［https://www.pmda.go.jp/files/000157674.pdf（accessed 2021-12-11）］（in Japanese）

2. 2) FDA guidance for industry. Rare diseases: common issues in drug development guidance for industry. January 2019.［https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-common-issues-drug-development-guidance-industry （accessed 2021-12-11）］

3. 3) European Medicines Agency. Guideline on clinical trials in small populations. July 27^th, 2006.［https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-trials-small-populations_en.pdf （accessed 2021-12-11）］

4. 4) Maeda K, Kaneko M, Narukawa M, Arato T. Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs. Orphanet J Rare Dis. 2017; 12（1）: 143-57. doi: 10.1186/s13023-017-0690-5.

5. 5) Sasinowski FJ. Quantum of effectiveness evidence in FDA's approval of orphan drugs. Drug Inf J. 2012; 46（2）: 238-63.